Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. faces a shareholder-led proxy contest: a coalition calling itself the Concerned Vaxart Stockholders, owning 1,515,343 shares, filed a definitive proxy statement and universal proxy card seeking to elect three nominees to the Board at the 2026 annual meeting.
The group asks for greater transparency, accountability, and Board-level reforms including a Clinical and Regulatory Affairs Committee and a Stockholder Relations Committee, and outlines strategic partnership ideas while emphasizing constructive engagement rather than disruption.
Concerned Vaxart Stockholders, a retail coalition holding 1,515,343 shares, filed a definitive proxy and a GOLD universal proxy card to elect three nominees — Daniel P. Houle, Mark Silverberg, DDS, MD, and Matthew M. Wallace, MD — to Vaxart’s board at the July 16, 2026 annual meeting. The group cites a 91% decline in the share price, approximately $343 million in cumulative losses since 2020, executive compensation of $5.2 million for fiscal 2025, issuance of 50 million new shares on June 13, 2024, and prior governance disputes including a rejected reverse stock split vote and disclosure concerns regarding a former director.
Vaxart, Inc. is soliciting proxies for its 2026 virtual Annual Meeting and is asking stockholders to vote FOR its six director nominees on the enclosed WHITE proxy card. The Board states that a stockholder, Daniel P. Houle, intends to nominate three opposing candidates and urges holders to discard any [•] proxy cards received from Mr. Houle.
The filing recounts prior engagement with Mr. Houle and other stockholders dating to August 2025, describes the Board’s candidate selection and recent appointment of James B. Breitmeyer, M.D., Ph.D., and summarizes prior governance actions including two reverse-split proposals in 2025, Nasdaq delisting actions, and related shareholder solicitations.
Vaxart, Inc. director Watson W. Mark reported an open-market purchase of 10,000 shares of Common Stock on May 22, 2026 at $0.653 per share. Following this transaction, he directly holds 134,125 shares of Vaxart common stock.
Vaxart proxy contest: A group led by Daniel P. Houle and five other participants is soliciting proxies to elect three nominees to Vaxart's six-member Board at the 2026 Annual Meeting, citing underperformance and governance concerns. The group reports beneficial ownership of 1,515,343 shares and will use a GOLD universal proxy card to solicit votes for a six-member slate.
The proxy statement details the nominees, voting mechanics for the virtual meeting, potential change-of-control effects under several equity and severance plans, and transaction schedules for the participants.
Vaxart, Inc. Chief Financial Officer Jeroen Nicolaas Grasman reported a tax-related share disposition connected to vested restricted stock units. On May 19, 2026, 31,395 shares of common stock were withheld by the company at $0.61 per share to satisfy income tax withholding and remittance obligations. This was a non-market transaction used to settle taxes rather than an open-market sale. After this withholding, Grasman directly held 545,605 shares of Vaxart common stock.
Vaxart, Inc. filed a preliminary proxy statement for its 2026 virtual Annual Meeting describing a contested director election: a stockholder, Daniel P. Houle, intends to nominate three director candidates in opposition to the Board’s slate. The Board unanimously recommends voting FOR its six nominees on the enclosed WHITE proxy card.
The filing discloses prior engagement with Mr. Houle and related investors, including that the Houle group collectively beneficially owned 1,739,782 shares (about 0.7%) as of February 20, 2026, and that Mr. Houle personally held 15,622 shares (less than 0.007%). The proxy recounts 2025 events including two reverse-split proposals, Nasdaq delisting and trading on OTCQX, the Board’s refreshment (appointment of Dr. James B. Breitmeyer on April 23, 2026), and governance and voting procedures under the universal proxy rules.
Vaxart, Inc. has filed preliminary proxy materials and issued an open letter ahead its 2026 Annual Meeting of Stockholders scheduled for July 16, 2026. The company highlights clinical progress for its oral vaccine platform, including a fully enrolled Phase 2b COVID-19 trial with about 5,400 participants and key data expected through early 2027. Vaxart states it has extended its cash runway into the second quarter of 2027 after cost reductions and dilutive financings, aiming to reach upcoming clinical milestones. The letter urges shareholders to back the board’s six director nominees in a contested election against three dissident candidates and notes the CEO holds more than 2.5 million shares. Deadlines for shareholder proposals and certain proxy-related notices are set at May 29, 2026.
Vaxart, Inc. registers up to 32,914,599 shares of common stock for resale by Lincoln Park Capital Fund, LLC, comprising up to 32,467,532 Purchase Shares and 447,067 Commitment Shares. The company is not selling shares here and will receive no proceeds from Lincoln Park’s resales; however, Vaxart may receive up to $25 million in gross proceeds from sales of Purchase Shares to Lincoln Park under a Purchase Agreement that provides committed equity financing. The prospectus states 241,973,011 shares outstanding prior to this registration and 274,440,543 shares outstanding after (reflecting potential issuance of Purchase Shares), and discloses recent market data of $0.74 per share (closing OTC price on May 7, 2026). The resale program permits Lincoln Park to sell registered shares in various ways and at varying prices; the Purchase Agreement contains formulas and timing mechanics governing purchases by Lincoln Park and limits on resale methods are described in the Plan of Distribution.